• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    D.R. Horton, Netflix And 3 Stocks To Watch Heading Into Thursday

    7/18/24 3:05:12 AM ET
    $ABT
    $DHI
    $NFLX
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Homebuilding
    Consumer Discretionary
    Get the next $ABT alert in real time by email

    With U.S. stock futures trading higher this morning on Thursday, some of the stocks that may grab investor focus today are as follows:

    • Wall Street expects D.R. Horton, Inc. (NYSE:DHI) to report quarterly earnings at $3.77 per share on revenue of $9.77 billion before the opening bell, according to data from Benzinga Pro. D.R. Horton shares gained 0.3% to $158.00 in after-hours trading.
    • Novartis AG (NYSE:NVS) posted upbeat results for its second quarter on Thursday. The company reported quarterly adjusted earnings of $1.97 per share, topping market estimates of $1.89 per share. Its sales came in at $12.512 billion beating expectations of $12.375 billion. Novartis shares rose 0.04% to $111.85 in the after-hours trading session.
    • Analysts expect Abbott Laboratories (NYSE:ABT) to post quarterly earnings at $1.10 per share on revenue of $10.37 billion. The company will release earnings before the markets open. Abbott shares rose 0.1% to $104.83 in after-hours trading.

    Check out our premarket coverage here

    • Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) reported better-than-expected second-quarter earnings. Taiwan Semiconductor Manufacturing shares gained 2.4% to $175.33 in the after-hours trading session.
    • Analysts expect Netflix, Inc. (NASDAQ:NFLX) to post quarterly earnings at $4.74 per share on revenue of $9.53 billion after the closing bell. Netflix shares rose 0.4% to $649.85 in after-hours trading.

    Check This Out:

    • Top 3 Industrials Stocks That Could Sink Your Portfolio This Month

    Photo courtesy: DR Horton

    Get the next $ABT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABT
    $DHI
    $NFLX
    $NVS

    CompanyDatePrice TargetRatingAnalyst
    Netflix Inc.
    $NFLX
    2/27/2026$115.00Outperform
    Evercore ISI
    Netflix Inc.
    $NFLX
    2/27/2026Neutral → Buy
    Arete
    Taiwan Semiconductor Manufacturing Company Ltd.
    $TSM
    2/13/2026$450.00Buy
    DA Davidson
    Novartis AG
    $NVS
    1/27/2026Buy
    Citigroup
    Netflix Inc.
    $NFLX
    1/23/2026$150.00 → $120.00Outperform
    Robert W. Baird
    Netflix Inc.
    $NFLX
    1/21/2026$115.00 → $112.00Buy
    TD Cowen
    Netflix Inc.
    $NFLX
    1/21/2026$121.00 → $95.00Outperform
    Wolfe Research
    Netflix Inc.
    $NFLX
    1/21/2026$145.00 → $120.00Buy
    Rothschild & Co Redburn
    More analyst ratings

    $ABT
    $DHI
    $NFLX
    $NVS
    SEC Filings

    View All

    SEC Form 8-K filed by Netflix Inc.

    8-K - NETFLIX INC (0001065280) (Filer)

    2/27/26 3:15:18 PM ET
    $NFLX
    Consumer Electronics/Video Chains
    Consumer Discretionary

    Abbott Laboratories filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - ABBOTT LABORATORIES (0000001800) (Filer)

    2/26/26 4:16:53 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Taiwan Semiconductor Manufacturing Company Ltd.

    6-K - TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD (0001046179) (Filer)

    2/26/26 6:02:01 AM ET
    $TSM
    Semiconductors
    Technology

    $ABT
    $DHI
    $NFLX
    $NVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy

    Adds Avidity's differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipelinePotentially unlocks multi-billion-dollar opportunities with planned product launches before 2030Strengthens late-stage pipeline to further support 2025-2030 net sales CAGR of 5-6% cc and mid to long term growth outlook Basel, February 27, 2026 -- Novartis AG (NYSE:NVS) today announced that it has successfully completed its acquisition of Avidity Biosciences, Inc. ("Avidity"). With the completion of the acquisition, Avidity is now an indirect, wholly owned subsidiary of Novartis. "Avidity's breakthrough science combined with

    2/27/26 9:00:00 AM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Netflix Declines to Raise Offer for Warner Bros.

    HOLLYWOOD, Calif., Feb. 26, 2026 /CNW/ -- Netflix, Inc. today announced that it has declined to raise its offer for Warner Bros. Netflix had earlier received notice from Warner Bros. Discovery (WBD) that its Board of Directors has determined Paramount Skydance's (PSKY) latest proposal constitutes a "Superior Proposal" under the terms of WBD's existing merger agreement with Netflix. Netflix issued the following statement in response from co-CEOs Ted Sarandos and Greg Peters: The transaction we negotiated would have created shareholder value with a clear path to regulatory approva

    2/26/26 5:45:00 PM ET
    $NFLX
    $PSKY
    $WBD
    Consumer Electronics/Video Chains
    Consumer Discretionary
    Broadcasting
    Industrials

    PARAMOUNT COMMENTS ON WARNER BROS. DISCOVERY BOARD'S DETERMINATION OF PARAMOUNT'S PROPOSAL AS SUPERIOR

    LOS ANGELES and NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Paramount Skydance Corporation (NASDAQ:PSKY) ("Paramount") confirms that it has been notified by Warner Bros. Discovery, Inc. (NASDAQ:WBD) ("WBD") that WBD's Board of Directors has determined that Paramount's $31 per share, all-cash proposal to acquire WBD is a "Company Superior Proposal" under the terms of WBD's merger agreement with Netflix, Inc. (NASDAQ:NFLX). David Ellison, Chairman and CEO of Paramount, said: "We are pleased WBD's Board has unanimously affirmed the superior value of our offer, which delivers to WBD shareholders superior value, certainty and speed to closing."Under the terms of Paramount's proposed merger agreement:

    2/26/26 4:35:00 PM ET
    $NFLX
    $PSKY
    $WBD
    Consumer Electronics/Video Chains
    Consumer Discretionary
    Broadcasting
    Industrials

    $ABT
    $DHI
    $NFLX
    $NVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Senior Vice President Shroff Eric was granted 10,873 units of Common shares without par value, increasing direct ownership by 36% to 41,257 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    2/26/26 7:24:53 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EXECUTIVE VICE PRESIDENT Scoggins Christopher J was granted 18,502 units of Common shares without par value, increasing direct ownership by 29% to 82,123 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    2/26/26 7:15:24 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP AND GROUP PRESIDENT Salvadori Daniel Gesua Sive was granted 21,644 units of Common shares without par value, increasing direct ownership by 16% to 153,877 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    2/26/26 7:02:35 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $DHI
    $NFLX
    $NVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Starks Daniel J bought $1,087,331 worth of Common shares without par value (10,000 units at $108.73), increasing direct ownership by 0.15% to 6,738,817 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    2/6/26 8:04:16 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHAIRMAN AND CEO Ford Robert B bought $2,013,967 worth of Common shares without par value (18,800 units at $107.13) (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    1/26/26 8:02:24 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $DHI
    $NFLX
    $NVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI resumed coverage on Netflix with a new price target

    Evercore ISI resumed coverage of Netflix with a rating of Outperform and set a new price target of $115.00

    2/27/26 8:31:30 AM ET
    $NFLX
    Consumer Electronics/Video Chains
    Consumer Discretionary

    Netflix upgraded by Arete

    Arete upgraded Netflix from Neutral to Buy

    2/27/26 8:22:06 AM ET
    $NFLX
    Consumer Electronics/Video Chains
    Consumer Discretionary

    DA Davidson initiated coverage on Taiwan Semiconductor Manufacturing with a new price target

    DA Davidson initiated coverage of Taiwan Semiconductor Manufacturing with a rating of Buy and set a new price target of $450.00

    2/13/26 8:32:20 AM ET
    $TSM
    Semiconductors
    Technology

    $ABT
    $DHI
    $NFLX
    $NVS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 1, 2024 - FDA Roundup: November 1, 2024

    For Immediate Release: November 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “FDA Takes Exciting Steps Toward Establishing the Rare Disease Innovation Hub,” by Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research (CDER) and Peter Marks, M.D., Ph.D., director

    11/1/24 3:18:19 PM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

    For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

    10/24/23 3:52:17 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $DHI
    $NFLX
    $NVS
    Leadership Updates

    Live Leadership Updates

    View All

    Abbott HeartMates Community Delivers Holiday Cheer in Hallmark Channel's New Movie "The More the Merrier"

    Movie to feature cameos from youth who have overcome significant heart health challenges and are part of the Abbott HeartMates community as well as professional football player and HeartMates ambassador Damar Hamlin "The More the Merrier" is the first Hallmark movie ever to include cameos from real-life individuals who have overcome cardiovascular challengesCharacter in the movie was inspired by Abbott HeartMates member Zeke Mankins, who has established a friendship with Hamlin through Hamlin's ambassador role for the HeartMates communityMovie premieres on Hallmark Channel on Nov. 28, 2025, during Hallmark's Merry Thanksgiving Weekend during "Countdown to Christmas"ABBOTT PARK, Ill., Nov. 4,

    11/4/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent

    This summer, Abbott and Real Madrid are hosting tryouts across the U.S. to form the 'Abbott Dream Team'Tryout attendees will learn about health and sports nutrition, encouraging them to promote healthy habits and an active lifestyle in their communitiesEleven selected players will travel to Madrid, train at Real Madrid's world-class facilities, and be instructed by Real Madrid coachesAmerican soccer icon Clint Dempsey will mentor the athletes throughout their journeyABBOTT PARK, Ill., May 7, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) announced today the creation of the inaugural 'Abbott Dream Team.' The program will seek out talented soccer players from across the United States and give them a o

    5/7/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

    Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With

    3/4/25 11:38:00 AM ET
    $ABT
    $TFX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $ABT
    $DHI
    $NFLX
    $NVS
    Financials

    Live finance-specific insights

    View All

    Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy

    Adds Avidity's differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipelinePotentially unlocks multi-billion-dollar opportunities with planned product launches before 2030Strengthens late-stage pipeline to further support 2025-2030 net sales CAGR of 5-6% cc and mid to long term growth outlook Basel, February 27, 2026 -- Novartis AG (NYSE:NVS) today announced that it has successfully completed its acquisition of Avidity Biosciences, Inc. ("Avidity"). With the completion of the acquisition, Avidity is now an indirect, wholly owned subsidiary of Novartis. "Avidity's breakthrough science combined with

    2/27/26 9:00:00 AM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott declares 409th consecutive quarterly dividend

    ABBOTT PARK, Ill., Feb. 20, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share. This marks the 409th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May 15, 2026, to shareholders of record at the close of business on April 15, 2026.Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years.About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio o

    2/20/26 11:38:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    D.R. Horton, Inc. to Release 2026 Second Quarter Earnings on April 21, 2026

    As previously announced, D.R. Horton, Inc. (NYSE:DHI), America's Builder, will release financial results for its second quarter ended March 31, 2026 on Tuesday, April 21, 2026 before the market opens. The Company will host a conference call that morning at 8:30 a.m. Eastern Time (ET). The dial-in number is 888-506-0062. When calling, please reference access code 659301. Participants are encouraged to call in five minutes before the call begins (8:25 a.m. ET). The call will also be webcast from the Company's website at investor.drhorton.com. A replay of the call will be available after 12:30 p.m. ET on Tuesday, April 21, 2026 at 877-481-4010. When calling, please reference replay passcode

    2/19/26 9:00:00 AM ET
    $DHI
    Homebuilding
    Consumer Discretionary

    $ABT
    $DHI
    $NFLX
    $NVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Novartis AG

    SC 13D/A - NOVARTIS AG (0001114448) (Filed by)

    10/17/24 4:01:28 PM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by D.R. Horton Inc. (Amendment)

    SC 13G/A - HORTON D R INC /DE/ (0000882184) (Subject)

    4/10/24 2:03:52 PM ET
    $DHI
    Homebuilding
    Consumer Discretionary

    SEC Form SC 13G/A filed by D.R. Horton Inc. (Amendment)

    SC 13G/A - HORTON D R INC /DE/ (0000882184) (Subject)

    2/14/24 1:02:50 PM ET
    $DHI
    Homebuilding
    Consumer Discretionary